SLQT 10-DAY DEADLINE ALERT: SelectQuote (SLQT) Faces Investor Lawsuit After DOJ Steps into Medicare Sales Probe - Hagens Berman

Core Viewpoint - SelectQuote Inc. is under legal scrutiny due to allegations of deceptive sales practices related to its Medicare Advantage plans, leading to a significant drop in its stock price and a class-action lawsuit from investors [1][4][5]. Legal Allegations - The lawsuit, Pahlkotter v. SelectQuote Inc. et al., claims that SelectQuote misled investors about its business model and regulatory risks from September 9, 2020, to May 1, 2025 [2][5]. - Allegations include that SelectQuote misrepresented its sales practices, promoting "unbiased advice" while actually steering customers towards higher-commission plans and accepting illegal kickbacks [3][7]. Market Impact - Following the DOJ's intervention, SelectQuote's stock price fell nearly 20% on May 1, 2025, and has since declined over 40% in the past six months, reflecting investor concerns about legal exposure and reputational damage [4][5]. Investigative Actions - Hagens Berman is investigating whether SelectQuote's revenue was artificially inflated through deceptive practices, indicating that the DOJ's involvement elevates the situation to a serious federal matter [6][8].